Nanolive closes a USD 20 million Series C-1 Round to drive significant growth of their Digital Assay solutions for live cell imaging and analysis
Nanolive SA, a leading live-cell imaging and analysis company, has successfully completed the initial closing of USD 20 million in the Series C-1 equity financing round of investment, led by a US-based and NASDAQ listed life science investor, and Taiwania Capital, the leading life science venture capital company based in Taiwan. This equity round of investment is also supported by investments from existing investors, including Swisscom Ventures, along with other partners. Nanolive is working closely with investors to secure a second close within ninety days.
Nanolive’s cutting-edge label-free microscope devices and state-of-the-art digital analytical solutions provide researchers and scientists working in the biopharmaceutical industry and laboratories with all the tools required to accelerate innovation in growth industries such as drug discovery and cell therapy.
Being able to screen thousands of living cells in 3D, without damaging them promises to radically advance how scientists study living cells. But the quantitative analytical suite Nanolive offers is a complete game-changer. Combining sub-cellular resolution with unique AI-assisted digital assays provides researchers and scientists a unique opportunity to study complex cell-drug perturbation dynamics and cell-cell interactions (e.g., T cell and target cell interactions), quantitatively, an approach that will revolutionize the cell-based assay phase of the drug discovery workflow.
“Life Sciences are undergoing a fundamental transformation, and Nanolive is at the heart of it,” says Dr. Yann Cotte, Nanolive’s CEO and Co-Founder. “We are honored to receive an investment from such an impressive group of investors who are excited to support us in our goal to transform the discovery and development of therapeutics. With this fundraising, we believe Nanolive is well-positioned to drive significant growth of our Digital Assay solutions and is at the leading edge of this global bioeconomy gold rush. We are selling the best picks and shovels for live-cell solutions.”“We are thrilled to be part of a Swiss-based innovative company that will revolutionize the drug discovery process,” said Michael L. Huang, Managing Partner of Taiwania Capital. “With this funding, Nanolive is well-positioned to provide crucial tools and solutions to pharmaceutical and biotech companies and research institutes for developing better therapies that would save millions of patient lives”.
In 2013, Nanolive won Venture Kick Stage 3 and participated in Venture Leaders Technology. They also were elected at the TOP 100 Swiss Startup Award four years in a row from 2015 to 2018.
Nanolive SA: Revolutionary live cell imaging and analysis
Nanolive has developed a disruptive proprietary technology, which allows for the very first time to explore a living cell in 3D without damaging it and instantly. By experiencing the living cell in a ... Read more
Related articles
Nanolive gets additional USD 2.2 million and closes its series C round at USD 22.2 million
read more
Nanolive wins the Swiss ICT Newcomer Award 2016
read more
Swisscom investit dans la start-up de l'EPFL Nanolive
read more
venturelab startups Nanolive and SwissLitho awarded by the “Oscar of invention”
read more
Nanolive remporte le Pionierpreis 2015
read more
Nanolive ouvre l'exploration cellulaire en 3D et en 3 minutes
read more
Nanolive closes its first financing round
read more